表紙
市場調査レポート

帯状疱疹後神経痛(PHN):疫学予測

EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 288594
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
帯状疱疹後神経痛(PHN):疫学予測 EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022
出版日: 2013年10月22日 ページ情報: 英文 45 Pages
概要

主要7市場(米国+欧州5カ国+日本)におけるPHN(ヘルペス後神経痛)有病者数は、2012年の約24万1,808人から2022年の約29万694人へと今後10年間で20.22%増加する見込みです。

当レポートでは、米国、欧州主要5カ国および日本におけるヘルペス後神経痛(PHN)の動向について調査し、疾病の概要、リスク因子と併存疾患、国・地域別の動向、年齢・性別の有病者予測などを提供しており、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾病の概要
  • リスク因子と併存疾患
    • 高齢者の帯状疱疹はPHN(帯状疱疹後神経痛)を約20倍発症しやすい
    • 帯状疱疹ワクチンは帯状疱疹およびPHNの罹患率を減らす
  • 世界の動向
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
  • 予測手法
  • ヘルペス後神経痛(PHN)の疫学予測
    • 発症例
    • 年齢別発症例
    • 性別発症例
    • 年齢標準化発症率
  • 議論

第4章 付録

  • 参考文献
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表リスト

目次
Product Code: GDHCER044

Postherpetic Neuralgia (PHN) is one of the most common complications of herpes zoster infection in elderly persons ages 60 years and older, worldwide. The main symptom of PHN is severe pain and allodynia (pain that results from a non-injurious stimulus to the skin). PHN is associated with a significant loss of activity levels and a reduced quality of life, particularly in the elderly. The strongest established risk factor for PHN is advancing age. Other possible risk factors for PHN include severity of acute herpes zoster pain, extent of rash, and duration of prodromal pain.

The number of incident cases of PHN in the 7MM will increase by 20.22% over the next decade, from 241,808 cases in 2012, to 290,694 cases in 2022. Age- and sex-specific incidence data for PHN and herpes zoster, as well as data for the proportion of herpes zoster patients developing PHN in the 7MM, were obtained or calculated from nationally-representative studies in each country to forecast the incident cases of PHN. To maintain a uniform methodology across the markets, GlobalData epidemiologists only used studies that defined PHN as pain persistent for three or more months.

Currently, there is no absolute preventative therapy for PHN. However, a vaccine is available to help prevent a herpes zoster infection; in turn, this vaccine helps reduce the incidence of PHN to an extent because PHN is the sequela of herpes zoster. The considerable increase in the aging population worldwide, coupled with the high risk for developing PHN in elderly herpes zoster patients are expected to impose a considerable burden on healthcare in the 7MM in future years.

Scope

  • The Postherpetic Neuralgia EpiCast Report provides an overview of the risk factors and global trends of postherpetic neuralgia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast (2012-2022) of the incident cases of postherpetic neuralgia segmented by age (in five-year increments beginning at age 50 and ending at age =85 years) and sex in the 7MM.
  • The postherpetic neuralgia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global postherpetic neuralgia market.
  • Quantify patient populations in the global postherpetic neuralgia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for postherpetic neuralgia therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Overview
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Elderly herpes zoster patients are almost 20 times more likely to develop PHN
    • 3.2.2. Herpes zoster vaccine reduces the morbidity of herpes zoster and PHN
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. France
    • 3.3.3. Germany
    • 3.3.4. Italy
    • 3.3.5. Spain
    • 3.3.6. UK
    • 3.3.7. Japan
  • 3.4. Forecast Metodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiological Forecast of Postherpetic Neuralgia (2012-2022)
    • 3.5.1. Incident Cases of PHN
    • 3.5.2. Age-Specific Incident Cases of PHN
    • 3.5.3. Sex-Specific Incident Cases of PHN
    • 3.5.4. Age-Standardized Incidence of PHN
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy
    • 4.2.4. Bonnie Bain, PhD, Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: 7MM, Sources of PHN Incidence Data
  • Table 2: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Table 3: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012
  • Table 4: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N (Row %), 2012

List of Figures

  • Figure 1: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Figure 2: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012
  • Figure 3: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N, 2012
  • Figure 4: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ≥50 Years, Men and Women, 2012
Back to Top